The Role of the Microbiome in the Development/Prevention of Food Allergies

微生物组在食物过敏发生/预防中的作用

基本信息

  • 批准号:
    7873387
  • 负责人:
  • 金额:
    $ 23.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-10 至 2012-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The prevalence of food allergies in Western cultures has steadily increased in the last several decades. While the cause of the increased incidence of allergies is likely to be multifactoral, a growing body of data supports the hypothesis that the composition of the gastrointestinal tract microbiota can be a contributing factor in the generation of allergic responses to otherwise innocuous food proteins. We have recently developed a mouse model of food allergy to chicken ovalbumin (OVA), which develops in response to microbiota perturbation. Ag-specific T cell responses will be tracked through the adoptive transfer of OVA-specific naive DO11.10 CD4 T-cells. Our hypothesis is that disturbances of the gastrointestinal microbiota, including the temporary or long-term outgrowth of yeast, promote the priming of a Th2 response to high dose food allergen exposure by disrupting regulatory networks and/or augmenting priming of mucosal Th2 responses. Therefore, strategies aimed at the microbiota (probiotics & prebiotcs) have the potential to restore defective regulatory responses and/or prevent allergen priming. Our aims are 1) to determine the cellular, humoral and cytokine responses in the mesenteric lymph nodes and lamina propria of microbiota-disrupted mice following oral delivery of OVA; 2) to determine the effect of a Lactobacillus probiotic, a prebiotic (scFOS) or the combination of the two on the cellular, humoral and cytokine responses in the mesenteric lymph nodes and lamina propria of microbiota-disrupted mice following oral delivery of OVA; 3) to determine the relationship between butyrate and all-trans retinoic acid on regulating the activity of CD103- and CD103+ dendritic cells isolated from the MLN and LP of untreated and microbiota-disrupted mice. Public Health Relevance Numerous epidemiologic studies have implicated disruptions of the indigenous microbiota (by antibiotics, diet, disease, or other environmental factors) as a causative factor in the development of mucosal inflammatory disorders, including food allergies. The data from this proposal will increase our understanding of the mechanisms connecting the indigenous microbiota and food allergies, including the mechanisms of probiosis to treat food allergies.
描述(由申请人提供):在过去的几十年里,西方文化中食物过敏的流行率稳步上升。虽然过敏发生率增加的原因可能是多因素的,但越来越多的数据支持这一假设,即胃肠道微生物群的组成可能是对其他无害食物蛋白质产生过敏反应的一个促成因素。我们最近开发了一种对鸡卵清蛋白(OVA)食物过敏的小鼠模型,其响应于微生物群扰动而发展。Ag特异性T细胞应答将通过OVA特异性初始DO11.10 CD 4 T细胞的过继转移来追踪。我们的假设是,胃肠道微生物群的紊乱,包括酵母菌的暂时或长期生长,通过破坏调节网络和/或增强粘膜Th 2应答的启动,促进Th 2应答对高剂量食物过敏原暴露的启动。因此,针对微生物群的策略(益生菌和益生元)有可能恢复有缺陷的调节反应和/或防止过敏原引发。我们的目的是:1)确定口服OVA后,微生物群破坏小鼠肠系膜淋巴结和固有层中的细胞、体液和细胞因子反应; 2)确定乳酸杆菌益生菌、益生元(scFOS)或两者的组合对细胞的影响,口服OVA后,微生物群破坏小鼠肠系膜淋巴结和固有层中的体液和细胞因子应答; 3)确定丁酸盐和全反式维甲酸在调节从未处理和微生物菌群破坏的小鼠的MLN和LP分离的CD 103-和CD 103+树突状细胞的活性方面的关系。 公共卫生相关性 许多流行病学研究表明,本地微生物群的破坏(抗生素,饮食,疾病或其他环境因素)是粘膜炎症性疾病(包括食物过敏)发展的致病因素。该提案的数据将增加我们对连接土著微生物群和食物过敏的机制的理解,包括益生菌治疗食物过敏的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gary B Huffnagle其他文献

Increase in dietary fiber dampens allergic responses in the lung
膳食纤维的增加抑制了肺部的过敏反应
  • DOI:
    10.1038/nm.3472
  • 发表时间:
    2014-02-06
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Gary B Huffnagle
  • 通讯作者:
    Gary B Huffnagle

Gary B Huffnagle的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gary B Huffnagle', 18)}}的其他基金

Neonatal RSV infection and alteration of allergic immune responses
新生儿 RSV 感染与过敏性免疫反应的改变
  • 批准号:
    10448373
  • 财政年份:
    2018
  • 资助金额:
    $ 23.2万
  • 项目类别:
Neonatal RSV infection and alteration of allergic immune responses
新生儿 RSV 感染与过敏性免疫反应的改变
  • 批准号:
    9763430
  • 财政年份:
    2018
  • 资助金额:
    $ 23.2万
  • 项目类别:
Neonatal RSV infection and alteration of allergic immune responses
新生儿 RSV 感染与过敏性免疫反应的改变
  • 批准号:
    10219079
  • 财政年份:
    2018
  • 资助金额:
    $ 23.2万
  • 项目类别:
Functional Analysis of the Pulmonary Microbiome during COPD
COPD 期间肺部微生物组的功能分析
  • 批准号:
    9542530
  • 财政年份:
    2017
  • 资助金额:
    $ 23.2万
  • 项目类别:
Pulmonary bacterial microbiome-epithelial cell interactions in COPD
COPD 中肺部细菌微生物组与上皮细胞的相互作用
  • 批准号:
    8509021
  • 财政年份:
    2012
  • 资助金额:
    $ 23.2万
  • 项目类别:
Pulmonary bacterial microbiome-epithelial cell interactions in COPD
COPD 中肺部细菌微生物组与上皮细胞的相互作用
  • 批准号:
    8337156
  • 财政年份:
    2012
  • 资助金额:
    $ 23.2万
  • 项目类别:
Pulmonary bacterial microbiome-epithelial cell interactions in COPD
COPD 中肺部细菌微生物组与上皮细胞的相互作用
  • 批准号:
    8669148
  • 财政年份:
    2012
  • 资助金额:
    $ 23.2万
  • 项目类别:
The Role of the Microbiome in the Development/Prevention of Food Allergies
微生物组在食物过敏发生/预防中的作用
  • 批准号:
    8141254
  • 财政年份:
    2010
  • 资助金额:
    $ 23.2万
  • 项目类别:
The Interplay Between Host Immunity and Clostridium difficile Pathogenesis
宿主免疫与艰难梭菌发病机制之间的相互作用
  • 批准号:
    8026744
  • 财政年份:
    2010
  • 资助金额:
    $ 23.2万
  • 项目类别:
Mucosal Mechanisms Linking Pulmonary and Gastrointestinal Inflammation/Immunity
连接肺部和胃肠道炎症/免疫的粘膜机制
  • 批准号:
    7898627
  • 财政年份:
    2009
  • 资助金额:
    $ 23.2万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 23.2万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 23.2万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 23.2万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 23.2万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 23.2万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 23.2万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 23.2万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 23.2万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 23.2万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 23.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了